Siemens Medical Solutions Usa, Inc.

Eli Lilly and Company

Threshold Pharmaceuticals, Inc.

Zhiyong Gao

Wei Zhang

Joseph C Walsh

Hartmuth C Kolb

Umesh B Gangadharmath

Dhanalakshmi Kasi

Qianwa Liang

Tieming Zhao

Henry Clifton Padgett

Farhad Karimi

Brian A Duclos

Thomas Lee Collier

Kai Chen

Gang Chen

Vani P Mocharla

Peter J H Scott

Chunfang Xia

Bing Wang

Eric Wang

Anjana Sinha

Peter Jh Scott

Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.

Imaging agents useful for identifying AD pathology

The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry

The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography. 

Nitro-imidazole hypoxia imaging agent

Nitro-imidazole hypoxia imaging agents

Growing community of inventors

Wynnewood, PA, United States of America

Zhiyong Gao